SURE SWITZERLAND: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 26 Jan 2019
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURE SWITZERLAND
- Sponsors Novo Nordisk
- 08 Nov 2018 Planned End Date changed from 27 Apr 2020 to 25 May 2020.
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.
- 22 Aug 2018 New trial record